A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 24, 2020

Primary Completion Date

March 31, 2027

Study Completion Date

October 31, 2027

Conditions
Multiple Sclerosis (MS)
Interventions
DRUG

Metformin

Each tablet contains 500mg of metformin hydrochloride

OTHER

Placebo

Each tablet contains no active drug ingredient

Trial Locations (1)

M5G 1X8

RECRUITING

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Queen's University

OTHER

collaborator

Ontario Institute for Regenerative Medicine

UNKNOWN

collaborator

Unity Health Toronto

OTHER

collaborator

Stem Cell Network

OTHER

collaborator

Multiple Sclerosis Society of Canada

OTHER

lead

The Hospital for Sick Children

OTHER